Hypertension and chronic kidney disease

Gargiulo, R.; Suhail, Faten; Lerma, Edgar V.

doi:10.1016/j.disamonth.2015.07.003

Cited by 39 publications

(34 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the current study, all CRF groups developed a hypertensive state that was lower in those under rHuEPO therapy; however, rHuEPO treatment induced a blood pressure rise in a dose‐dependent manner. The reduction of blood pressure in the context of CKD may present benefits, as it reduces albumin excretion, thus limiting the progression of CKD and the risk of cardiovascular disease . As observed by others, we found that high blood pressure is associated with increased albumin urinary excretion, but without alterations in other markers of renal function (Table ).…”

Section: Discussionsupporting

confidence: 82%

“…The reduction of blood pressure in the context of CKD may present benefits, as it reduces albumin excretion, thus limiting the progression of CKD and the risk of cardiovascular disease. 48 As observed by others, 9,49 we found that high blood pressure is associated with increased albumin urinary excretion, but without alterations in other markers of renal function ( Table 2). The CRF600 group presented the highest increase in blood pressure, as compared with the other rHuEPOtreated CRF groups, probably due to the increased blood viscosity.…”

Section: Discussionsupporting

confidence: 79%

See 1 more Smart Citation

Renal risk‐benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model – hypertension, anaemia, inflammation and drug dose

Ribeiro

Garrido

Fernandes

et al. 2016

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Clinical studies showed that high doses of recombinant human erythropoietin (rHuEPO) used to correct anaemia in chronic kidney disease (CKD) hyporesponsive patients may lead to deleterious effects. The aim of this study was to analyze the effects of rHuEPO in doses usually used to correct CKD-anaemia (100, 200 IU/kg body weight (BW) per week) and in higher doses used in the treatment of hyporesponsive patients (400, 600 IU/kg BW per week), focusing on renal damage, hypoxia, inflammation and fibrosis. Male Wistar rats with chronic renal failure (CRF) induced by 5/6 nephrectomy were treated with rHuEPO or with vehicle, over a 3-week period. Haematological, biochemical and renal function analyses were performed. Kidney and liver mRNA levels were evaluated by quantitative real-time polymerase chain reaction (qPCR) and protein expression by Western blot and immunohistochemistry. Kidney histopathological evaluations were also performed. The CRF group developed anaemia, hypertension and a high score of renal histopathologic lesions. Correction of anaemia was achieved with all rHuEPO doses, with improvement in hypertension, renal function and renal lesions. In addition, the higher rHuEPO doses also improved inflammation. Blood pressure was reduced in all rHuEPO-treated groups, compared to the CRF group, but increased in a dose-dependent manner. The current study showed that rHuEPO treatment corrected anaemia and improved urinary albumin excretion, particularly at lower doses. In addition, it is suggested that a short-term treatment with high doses, used to overcome an episode of hyporesponsiveness to rHuEPO therapy, can present benefits by reducing inflammation, without worsening of renal lesions; however, the pro-hypertensive effect should be considered, and carefully managed to avoid a negative cardiorenal impact.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionsupporting

confidence: 79%

Renal risk‐benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model – hypertension, anaemia, inflammation and drug dose

Ribeiro

Garrido

Fernandes

et al. 2016

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…According to previous studies, 44% of new end stage renal disease patients have diabetes, 32 and 80% to 85% of CKD patients have hypertension. 33 We gave effort to exclude or adjust well-known risk factors such as hypertension, diabetes, dyslipidemia, obesity, smoking, and alcohol intake; therefore, we think that CKD will have little effect on the results. Second, aminotransferase was measured in different methods by each participating institution, and the normal range of aminotransferase and assay results may be different slightly between institutions.…”

Section: Discussionmentioning

confidence: 99%

Association Between Change in Serum Aminotransferase and Mortality

et al. 2016

View full text Add to dashboard Cite

There is little information on how the change in serum aminotransferase affects mortality. We investigated the association between changes in serum aminotransferase levels and mortality from all causes, cardiovascular disease (CVD), and liver disease.Three percent of men from the Korean National Health Insurance database were sampled randomly at the end of 2002. After excluding patients with cancer, CVD, CVD risk factors, or liver disease, those who participated in 2 consecutive rounds of the national health screening examination were included (n = 68,431). The primary outcome was CVD mortality. Secondary outcomes were liver disease mortality and all-cause mortality. Change in metabolic profiles was analyzed based on changes in liver enzyme levels. Elevated levels of serum aminotransferase were associated with CVD, liver disease, and all-cause mortality. Men who had sustained elevation of serum aminotransferase during 2 subsequent liver enzyme tests showed a significantly higher risk of CVD mortality (adjusted hazard ratio [aHR] 1.95; 95% confidence interval [CI] 1.07–3.56, 2.29; 1.27–4.12) than the sustained normal group. In contrast, the normalization group (aHR 1.52, 95% CI 0.82–2.81 for aspartate aminotransferase [AST]; aHR 1.35, 95% CI 0.70–2.61 for alanine aminotransferase [ALT]) and the new elevation group (aHR 1.27, 0.66–2.44 for AST; aHR 0.99, 95% CI 0.49–2.20 for ALT) were not different from the sustained normal group in CVD mortality.Individuals with serum aminotransferase elevation, particularly when sustained, are at higher risk of mortality, and should receive appropriate medical attention.

show abstract

“…The kidney is one of several organ systems that are adversely affected by hypertension and is one of the leading causes of chronic kidney diseases (CKD) resulting in kidney dysfunction [5, 6]. It is believed that CKD affects over 20 million adults in the US, with approximately 60% of these cases having associated hypertension [7].…”

Section: Introductionmentioning

confidence: 99%

Homocysteine and hydrogen sulfide in epigenetic, metabolic and microbiota related renovascular hypertension

Weber

Pushpakumar

Tyagi

et al. 2016

Pharmacological Research

View full text Add to dashboard Cite

Over the past several years, hydrogen sulfide (H2S) has been shown to be an important player in a variety of physiological functions, including neuromodulation, vasodilation, oxidant regulation, inflammation, and angiogenesis. H2S is synthesized primarily through metabolic processes from the amino acid cysteine and homocysteine in various organ systems including neuronal, cardiovascular, gastrointestinal, and kidney. Derangement of cysteine and homocysteine metabolism and clearance, particularly in the renal vasculature, leads to H2S biosynthesis deregulation causing or contributing to existing high blood pressure. While a variety of environmental influences, such as diet can have an effect on H2S regulation and function, genetic factors, and more recently epigenetics, also have a vital role in H2S regulation and function, and therefore disease initiation and progression. In addition, new research into the role of gut microbiota in the development of hypertension has highlighted the need to further explore these microorganisms and how they influence the levels of H2S throughout the body and possibly exploiting microbiota for use of hypertension treatment. In this review, we summarize recent advances in the field of hypertension research emphasizing renal contribution and how H2S physiology can be exploited as a possible therapeutic strategy to ameliorate kidney dysfunction as well as to control blood pressure.

show abstract

Hypertension and chronic kidney disease

Cited by 39 publications

References 44 publications

Renal risk‐benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model – hypertension, anaemia, inflammation and drug dose

Renal risk‐benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model – hypertension, anaemia, inflammation and drug dose

Association Between Change in Serum Aminotransferase and Mortality

Homocysteine and hydrogen sulfide in epigenetic, metabolic and microbiota related renovascular hypertension

Contact Info

Product

Resources

About